Patient-derived xenografts (PDX) are preclinical models for precision cancer medicine. PDX models are highly recognized for recapitulating phenotype-genotype associations of their matched patient ...

Assessing risk of recurrence for nonmetastatic triple-negative breast cancer (TNBC) is a key determinant of therapeutic strategy. The best predictor of recurrence risk is failure to achieve a ...

A new review published in Genes & Diseases highlights the critical role of patient-derived xenograft (PDX) models, offering a powerful preclinical platform that more accurately mimics human tumors.

Cambridge, UK, 26 May 2017: Horizon Discovery Group plc (LSE: HZD) ("Horizon"), the world leader in the application of gene editing technologies, today announced it has added four BRAF-resistant ...

HACKENSACK, NJ / ACCESS Newswire / July 8, 2025 / Champions Oncology (NASDAQ:CSBR) a leading translational oncology research organization, today announced the full commercial launch of its ...

Small cell lung cancer, or SCLC, is aggressive, lethal and particularly cruel because chemotherapy initially works so well. But within just a few months, SCLC becomes resistant to drugs and dashes ...

Researchers from the National Health Research Institutes of Taiwan described the efficacy of BPR1J481, a multitarget tyrosine kinase inhibitor in PDX-derived colorectal cancer cells, which retain the ...

Circulating tumor cells (CTCs) are malignant cells that have detached from primary or metastatic tumor sites and entered the peripheral bloodstream. As a critical component of liquid biopsy, the ...